Axsome Therapeutics Inc (AXSM)

Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Zacks Investment Research

First Turn Management LLC Acquires Shares of 295,428 Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

MarketBeat

Axsome: 1Q Earnings Snapshot - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options - Yahoo News UK

Yahoo News UK

Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options - Yahoo Movies UK

Yahoo Movies UK

CFO & Principal Accounting Officer Nick Pizzie Just Bought Shares In Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Yahoo Canada Shine On

Yahoo Canada Shine On

21,086 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Truist Financial Corp - MarketBeat

MarketBeat

Prediction: These 2 Growth Stocks Could Triple By 2030

The Motley Fool

Truist Financial Corp Takes $1.68 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World

Defense World

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Forecasted to Earn Q2 2024 Earnings of ($1.31) Per Share - Defense World

Defense World

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $121.92 Consensus PT from Brokerages - MarketBeat

MarketBeat

HC Wainwright Analysts Cut Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

MarketBeat

HC Wainwright Brokers Lower Earnings Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) - Defense World

Defense World

Why Axsome Therapeutics Stock Is A Promising Stock Pick In CNS Treatments (NASDAQ:AXSM) - Seeking Alpha

Seeking Alpha

Equities Analysts Set Expectations for Axsome Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:AXSM) - Defense World

Defense World

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Expected to Post Q2 2024 Earnings of ($1.35) Per Share - Defense World

Defense World

Research Analysts Offer Predictions for Axsome Therapeutics, Inc.'s Q3 2025 Earnings (NASDAQ:AXSM) - MarketBeat

MarketBeat

Axsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

Yahoo Finance

Research Analysts Issue Forecasts for Axsome Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:AXSM) - Defense World

Defense World

Axsome Therapeutics (NASDAQ:AXSM) Given New $106.00 Price Target at Mizuho - MarketBeat

MarketBeat

Axsome Therapeutics to Present at Upcoming Investor Conferences - GlobeNewswire

GlobeNewswire

Axsome Therapeutics (NASDAQ:AXSM) Price Target Increased to $112.00 by Analysts at Robert W. Baird - Defense World

Defense World

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates - Yahoo Canada Finance

Yahoo Canada Finance

Axsome Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St

Simply Wall St

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates - Yahoo Finance

Yahoo Finance

Earnings call: Axsome Therapeutics sees robust growth in Q1 2024 - Investing.com

Investing.com

Earnings call: Axsome Therapeutics sees robust growth in Q1 2024 - Investing.com

Investing.com

Axsome: Q1 Earnings Snapshot - Houston Chronicle

Houston Chronicle

Axsome: Q1 Earnings Snapshot - Darien Times

Darien Times

Axsome Therapeutics (AXSM) Q1 2024 Earnings Call Transcript

The Motley Fool

Axsome Therapeutics Inc earnings missed by $0.22, revenue topped estimates - Investing.com South Africa

Investing.com South Africa

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

GlobeNewswire

Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - The Bakersfield Californian

The Bakersfield Californian

Axsome: Q1 Earnings Snapshot - Milford Mirror

Milford Mirror

Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings? - MSN

MSN

Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?

Zacks Investment Research

Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings? - Zacks Investment Research

Zacks Investment Research

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research

Cannell & Co. Decreases Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

MarketBeat

TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Zacks Investment Research

Axsome Therapeutics Recognizes May as Mental Health Awareness Month - GlobeNewswire

GlobeNewswire

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term ... - GlobeNewswire

GlobeNewswire

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term ... - GlobeNewswire

GlobeNewswire

Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights

Benzinga

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Zacks Investment Research

Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Up to $71.71 - MarketBeat

MarketBeat

Axsome Therapeutics, Inc. to Post Q1 2024 Earnings of ($1.26) Per Share, William Blair Forecasts (NASDAQ:AXSM) - Defense World

Defense World

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term ... - GlobeNewswire

GlobeNewswire

Billionaires Are Buying These 2 Ultra-High Yield Dividend Stocks Hand Over Fist. Are They Smart Buys for Your Portfolio?

The Motley Fool

Solriamfetol's Cognitive and Wake-Promoting Effects Explored - Sleep Review

Sleep Review